Climb Bio (CLYM) News Today $2.38 +0.19 (+8.68%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Climb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at Baird R WAugust 18, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Coverage Initiated at Robert W. BairdAugust 18, 2025 | americanbankingnews.comAnalysts Set Climb Bio, Inc. (NASDAQ:CLYM) Target Price at $9.00August 18, 2025 | americanbankingnews.comClimb Bio, Inc. (NASDAQ:CLYM) surges 12%; private equity firms who own 54% shares profited along with institutionsAugust 17, 2025 | finance.yahoo.comQ3 Earnings Forecast for Climb Bio Issued By Leerink PartnrsAugust 17, 2025 | marketbeat.comClimb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from AnalystsAugust 17, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Now Covered by Robert W. BairdAugust 17, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Raised to Strong-Buy at Baird R WAugust 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for Climb Bio Q3 Earnings?August 17, 2025 | americanbankingnews.comBaird Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationAugust 16, 2025 | msn.comClimb Bio initiated with an Outperform at Baird on budoprutug potentialAugust 15, 2025 | msn.comClimb Bio initiated with an Outperform at BairdAugust 14, 2025 | msn.comClimb Bio (NASDAQ:CLYM) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPSAugust 13, 2025 | marketbeat.comClimb Bio, Inc.: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 12, 2025 | finanznachrichten.deClimb Bio reports Q2 EPS (13c) vs ($1.81) last yearAugust 12, 2025 | msn.comClimb Bio, Inc. Advances Clinical Trials for Budoprutug in ITP and SLE, with Upcoming Initiation of pMN Trial and CLYM116 Webcast EventAugust 12, 2025 | quiverquant.comQClimb Bio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 12, 2025 | globenewswire.comClimb Bio (CLYM) to Release Earnings on WednesdayAugust 12, 2025 | americanbankingnews.comClimb Bio (CLYM) Expected to Announce Quarterly Earnings on WednesdayAugust 7, 2025 | marketbeat.comClimb Bio Inc (CLYM) - Yahoo FinanceAugust 5, 2025 | finance.yahoo.comPeapod Lane Capital LLC Buys New Shares in Climb Bio, Inc. (NASDAQ:CLYM)July 10, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Trading Down 4% - Should You Sell?July 2, 2025 | marketbeat.comClimb Bio appoints Edgar D. Charles as Chief Medical OfficerJune 18, 2025 | msn.comClimb Bio Appoints Cindy Driscoll as Finance VPJune 18, 2025 | tipranks.comOppenheimer Initiates Coverage of Climb Bio (CLYM) with Outperform RecommendationJune 7, 2025 | msn.comClimb Bio (NASDAQ:CLYM) Earns Outperform Rating from Analysts at OppenheimerJune 6, 2025 | marketbeat.comCLYM Climb Bio, Inc.May 30, 2025 | seekingalpha.comClimb Bio (NASDAQ:CLYM) Coverage Initiated at BTIG ResearchMay 24, 2025 | marketbeat.comBTIG sets Climb Bio stock Buy rating, $7 targetMay 23, 2025 | investing.comClimb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | finanznachrichten.deWhat is Leerink Partnrs' Estimate for Climb Bio Q2 Earnings?May 20, 2025 | marketbeat.comClimb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 19, 2025 | globenewswire.comClimb Bio (CLYM) Expected to Announce Earnings on WednesdayMay 16, 2025 | marketbeat.comClimb Bio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 14, 2025 | globenewswire.comClimb Bio (NASDAQ:CLYM) Trading Down 2.4% - Should You Sell?April 24, 2025 | marketbeat.comExec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REXApril 10, 2025 | finance.yahoo.comClimb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to boardApril 2, 2025 | markets.businessinsider.comQ2 Earnings Estimate for Climb Bio Issued By Leerink PartnrsMarch 29, 2025 | marketbeat.comClimb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update ReportMarch 27, 2025 | finance.yahoo.comClimb Bio to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 27, 2025 | globenewswire.comClimb Bio Advances Clinical Trials and Expands PipelineMarch 26, 2025 | tipranks.comClimb Bio (NASDAQ:CLYM) Releases Earnings Results, Beats Estimates By $0.02 EPSMarch 26, 2025 | marketbeat.comClimb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 26, 2025 | finanznachrichten.deClimb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdatesMarch 25, 2025 | globenewswire.comClimb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation ReportMarch 20, 2025 | finance.yahoo.comClimb Bio (CLYM) Expected to Announce Earnings on ThursdayMarch 20, 2025 | marketbeat.comClimb Bio (NASDAQ:CLYM) Shares Down 6.9% - Should You Sell?March 4, 2025 | marketbeat.comClimb Bio to Present at Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comClimb Bio appoints Perrin Wilson as CBOFebruary 24, 2025 | markets.businessinsider.comClimb Bio Appoints Perrin Wilson, Ph.D., as Chief Business OfficerFebruary 24, 2025 | globenewswire.com Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address CLYM Media Mentions By Week CLYM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLYM News Sentiment▼0.730.64▲Average Medical News Sentiment CLYM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLYM Articles This Week▼141▲CLYM Articles Average Week Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Prothena News Today Compass Therapeutics News Today Kamada News Today Evolus News Today Tectonic Therapeutic News Today COMPASS Pathways News Today PureTech Health News Today Aquestive Therapeutics News Today Replimune Group News Today Zhengye Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLYM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access